AVENUE THERAPEUTICS INC (ATXI)

US05360L4032 - Common Stock

3.73  +0.1 (+2.75%)

After market: 3.73 0 (0%)

News Image
4 days ago - InvestorPlace

ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q1 2024

ATXI stock results show that Avenue Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.

News Image
4 days ago - BusinessInsider

ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avenue Therapeutics (NASDAQ:ATXI) just reported results for the first quarter o...

News Image
5 days ago - Avenue Therapeutics

Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) --...

News Image
20 days ago - Chartmill

What's going on in today's session

Monday's session: top gainers and losers

News Image
21 days ago - Chartmill

Which stocks are experiencing notable movement on Monday?

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

News Image
21 days ago - Chartmill

Top movers in Monday's pre-market session

Curious about the stocks that are showing activity before the opening bell on Monday?

News Image
21 days ago - Avenue Therapeutics

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...

News Image
26 days ago - Avenue Therapeutics

Avenue Therapeutics Announces Reverse Stock Split

MIAMI, April 24, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...

News Image
2 months ago - Avenue Therapeutics

Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024

MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...

News Image
2 months ago - BusinessInsider

ATXI Stock Earnings: Avenue Therapeutics Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Avenue Therapeutics (NASDAQ:ATXI) just reported results for the fourth quarter ...

News Image
2 months ago - InvestorPlace

ATXI Stock Earnings: Avenue Therapeutics Beats EPS for Q4 2023

ATXI stock results show that Avenue Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

News Image
2 months ago - Avenue Therapeutics

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

- Enrollment completed in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data expected in second quarter of 2024 - ...

News Image
2 months ago - Avenue Therapeutics

Avenue Therapeutics Receives Positive Listing Determination from Nasdaq

MIAMI, March 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...

News Image
2 months ago - Avenue Therapeutics

Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting

BAER-101 demonstrated full suppression of seizure activity in SynapCell's GAERS model of absence epilepsy, a proven indicator of efficacy in anti-seizure...

News Image
3 months ago - Avenue Therapeutics

Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy

-In vivo data supports BAER-101’s unique ability to significantly suppress seizures using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg...

News Image
4 months ago - Avenue Therapeutics

Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused...

News Image
5 months ago - Avenue Therapeutics

Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds

MIAMI, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused...

News Image
5 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning!